Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 4, 2006. The document serves as a notification of transactions involving a Director, specifically Dr. T Yamada, regarding American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of insider trading activity and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details a specific transaction by a Director.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this filing. The content is restricted to the notification of Dr. T Yamada's exercise of options and subsequent sale of ADSs.
Important Facts for Investors
- Transaction Date: May 3, 2006.
- Director Involved: Dr. T Yamada.
- Activity: Exercise of options over 21,380 ADSs granted on November 21, 1996, under the SmithKline Beecham US 1991 Share Option Plan.
- Exercise Price: $28.16 per ADS.
- Sale Price: $56.77 per ADS (immediately following exercise).
- Notification Date: The Company was advised of these transactions on May 4, 2006.